PHARMACY

Halozyme Therapeutics yields strong results in Q1

BY Alaric DeArment

SAN DIEGO Halozyme Therapeutics reported significant product development progress in its first quarter 2009 financial results, released Friday.

The San Diego-based drug maker of endocrinology, oncology and dermatology drugs said its progress included two new phase 1 trials, one with Roche and another for PEGPH20, a drug designed to treat refractory cancer patients.

 

“We anticipate advancing additional clinical studies during the course of 2009 and will present interim results from our phase 2 insulin-PH20 study in Type 1 diabetic patients in early June,” Halozyme president and CEO Jonathan Lim said.

Net losses for the company were $14.7 million, compared with $10 million in first quarter 2008. Revenue was $2.8 million, compared with $1.8 million during the same period last year.

Research and development expenses increased to $14 million, from $8.4 million in first quarter 2008, while selling, general and administrative expenses declined to $3.5 million, from $4.2 million a year ago.

Cash and cash equivalents were $62.1 million, compared with $92.6 million for first quarter 2008.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

OSI Pharmaceuticals EVP to present portfolio at diabetes and obesity conference

BY Allison Cerra

MELVILLE, N.Y. OSI Pharmaceuticals, Inc. announced Thursday that Anker Lundemose, M.D., EVP of OSI Pharmaceuticals will present at the Canaccord Adams Conference in New York, N.Y. on Tuesday, May 12, 2009 at 8:40 a.m. (Eastern Time).

Lundemose will provide an overview on the company’s diabetes/obesity product portfolio and business developments.

The presentation will be webcast live and may be accessed by visiting OSI’s Web site at www.osip.com. A replay of the Webcast will also be available on the Company’s Web site until May 26, 2009.

OSI Pharmaceuticals discover, develop and commercialize high-quality, novel and differentiated personalized medicines designed to extend life and improve the quality of life for patients with cancer and diabetes/obesity.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA grants priority review to Prevnar 13

BY Alaric DeArment

COLLEGEVILLE, Pa. The Food and Drug Administration has granted priority review to Wyeth Pharmaceuticals’ application for the pneumococcal vaccine Prevnar 13 (diphtheria CRM[197] protein).

The company submitted the application for the vaccine, a 13-valent conjugate vaccine, on March 31.

Wyeth said it is seeking approval for Prevnar 13 for the prevention of invasive pneumococcal disease and otitis media caused by the 13 serotypes in the vaccine in children ages 2 months to 5 years. Prevnar 13 includes six serotypes in addition to the seven in the earlier version of Prevnar.

“Since its launch in 2000, our seven-valent pneumococcal vaccine, Prevnar, has significantly reduced the incidence of pneumococcal disease among infants and young children in the United States,” Wyeth Pharmaceuticals EVP vaccine research and development Emilio Emini said. “Recently, however, disease due to pneumococcal serotypes not found in Prevnar, particularly serotype 19A, have increased in prevalence in many regions of the world and are a significant public health concern.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?